









Markets
/
Stocks
/
nasdaq-atai
/

ATAI Life Sciences NV

ATAI

4.720USD

+0.110+2.39%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.00BMarket Cap

LossP/E TTM



ATAI Life Sciences NV

4.720

+0.110+2.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

97 / 507

Overall Ranking

214 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

11.286

Target Price

+142.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.19% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 308.00K.

Undervalued

The company’s latest PE is -6.62, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.77M shares, increasing 1.68% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 1.55M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.22, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 719.00K, representing a year-over-year increase of 163.37%, while its net profit experienced a year-over-year increase of 51.62%.

Score

Industry at a Glance

Previous score

6.24

Change

0.98



Financials

8.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.80

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.85

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.48

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -6.62, which is -71.76% below the recent high of -1.87 and 46.38% above the recent low of -3.55.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 97/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for ATAI Life Sciences NV is 11.00, with a high of 16.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

11.286

Target Price

+144.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

ATAI Life Sciences NV

ATAI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 7.44, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 5.35 and the support level at 3.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.48

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.079

Neutral

RSI(14)

61.123

Neutral

STOCH(KDJ)(9,3,3)

44.922

Neutral

ATR(14)

0.289

Low Volatility

CCI(14)

174.928

Buy

Williams %R

40.719

Buy

TRIX(12,20)

0.608

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.652

Buy

MA10

4.656

Buy

MA20

4.628

Buy

MA50

4.030

Buy

MA100

3.042

Buy

MA200

2.304

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 18.27%, representing a quarter-over-quarter decrease of 5.44%. The largest institutional shareholder is Catherine Wood, holding a total of 1.55M shares, representing 0.72% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Apeiron Investment Group Ltd

44.17M

+4.25%

Galaxy Group Investments LLC

10.80M

+27.44%

UBS Financial Services, Inc.

3.87M

+550.21%

Brand (Florian Olaf)

5.29M

+0.98%

Pale Fire Capital SE

2.59M

+421.23%

Morgan Stanley Investment Management Inc. (US)

1.84M

-0.38%

Morgan Stanley & Co. LLC

1.33M

-3.93%

Millennium Management LLC

1.14M

+15.71%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.23, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.